There is no Medicare coverage criteria addressing this service; therefore, the Company policy is applicable.
Subject to the terms and conditions of the applicable Evidence of Coverage, the use of computer-aided detection (CAD) systems with chest radiographs is not eligible for payment under the medical benefits of the Company’s Medicare Advantage products because the service is considered experimental/investigational and, therefore, not covered.
Services that are experimental/investigational are excluded for the Company’s Medicare Advantage products. Therefore, they are not eligible for reimbursement consideration.
US FOOD AND DRUG ADMINISTRATION (FDA) STATUS
The RapidScreen™ RS-2000 (Deus Technologies, Rockville, MD) received premarket approval (PMA) on July 12, 2001, from the FDA for use as a computer-aided detection (CAD) system.